🚀 Immune checkpoint inhibitors have transformed cancer care—but they come with a cardiovascular shadow.

A new International Cardio-Oncology Society (IC-OS) position statement offers the clearest guidance yet on myocarditis, pericarditis, arrhythmias, ACS, and noninflammatory HF linked to ICI therapy. 🫀💡

Key insights include:

• Early recognition with troponin, ECG, and CMR 🧪📊

• Smoldering vs. nonsevere vs. fulminant myocarditis distinctions 🔍

• Steroid-first management and the evolving role of abatacept + JAK inhibitors 💊

• Nuanced approaches to ICI rechallenge when cancer control demands it 🔄🎯

• The essential role of multidisciplinary cardio-oncology teams 🤝

This is a must-read for anyone navigating the intersection of oncology, cardiology, and immunotherapy. 🌐🔥